Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Canada could approve COVID-19 vaccines early next year -regulator

11/23/2020 | 03:40pm EST

TORONTO, Nov 23 (Reuters) - Canada could approve one or more COVID-19 vaccines early in the first quarter of 2021, under a new, accelerated process similar to the U.S. emergency use authorization, according to Health Canada, the country's drug regulator.

An interim order signed by Canada's health minister on Sept. 16 created an expedited, temporary review system for COVID-19 drugs or vaccines, which otherwise could have taken a year to evaluate.

Because the system is new, it was not immediately clear how the process would compare to the U.S. regime.

But on Friday, Canada made its first authorization under the new system, for Eli Lilly's treatment bamlanivimab, just under two weeks after its U.S. emergency authorization.

Separately, in a statement late on Thursday, Health Canada told Reuters it was working to "align regulatory approaches" with international partners.

"It is important to note that requirements in Canada for vaccine approval under the Interim Order are comparable to those necessary for an Emergency Use Authorization (EUA) in the US," said the statement. "Overall, there is good consensus among regulators globally with regard to data requirements for COVID vaccines."

The statement said approvals could come early in the first quarter of 2021, but that timelines would be clearer once vaccine makers' applications were complete.

Canadian officials said in October that the expedited process would likely take months, whereas normal approvals take about a year.

Health Canada had already approved one COVID-19 treatment, Gilead's remdesivir, more quickly than that, citing the "high unmet medical need and emergency context of the COVID-19 pandemic." It received Gilead's application on June 19 and released its decision on July 27.

The new interim order system allows for rolling submissions, where companies can file partial applications and then add to them as more data is available. Moderna, Pfizer and AstraZeneca began rolling applications in October.

To grant approval, the health minister must find that the benefits of a new drug or vaccine outweigh its risks, while considering "the urgent public health need caused by COVID-19," according to regulatory documents. (Reporting by Allison Martell; Editing by Tom Brown)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.66% 7777 Delayed Quote.6.19%
GILEAD SCIENCES, INC. -0.06% 66.94 Delayed Quote.14.90%
MODERNA, INC. -1.47% 131.02 Delayed Quote.25.41%
All news about ASTRAZENECA PLC
03:26pTHE LATEST : Chicago opens restaurants, some bars with limits
AQ
01:09pUK vaccine roll-out speeds up but doctors want quicker second dose
RE
12:49pAstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
DJ
11:41aPFIZER : UK doctors seek review of 12-week gap between vaccine doses
AQ
11:38aItaly PM says vaccine supply delays are serious contract violations
RE
06:06aTHE LATEST : N.Y. seniors, churches to get vaccine prep kits
AQ
03:45aASTRAZENECA : UK doctors call for shorter gap between Pfizer vaccine doses
RE
01/22Health Care Down Amid Vaccine-Rollout Concerns -- Health Care Roundup
DJ
01/22THE LATEST : Online vaccine appointments filling up in Kansas
AQ
01/22ALEXION INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
BU
More news
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.19%139 483
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159